Ingmar Hoerr
GermanyentrepreneurMale5.5Global Dominance: 0.01%Ingmar Hoerr is the co-founder of CureVac, a biopharmaceutical company that specializes in mRNA technology for vaccine development. He has been instrumental in the company's evolution from focusing on infectious diseases to concentrating on cancer immunotherapies. Recently, he was in the news following the announcement of CureVac's acquisition by BioNTech, which he views as a positive development for the European biotech landscape, believing it will enhance innovation in mRNA technology.
Country presence
Recent news mentions
Ingmar Hoerr, the founder of Curevac, accused Biontech of deception regarding their merger agreement.
Keine Käufer gefunden: Drei deutsche Biontech-Standorte werden geschlossen - WirtschaftGermany· 2026-09-28
Ingmar Hoerr is the co-founder of Curevac and has previously served as its CEO.
Curevac in Tübingen: Übernahme durch Biontech und Standorte in Gefahr - WirtschaftGermany· 2026-09-19Ingmar Hoerr, the founder of Curevac, views the planned acquisition as a positive sign for Europe.
Biontech kauft Konkurrenten Curevac - WirtschaftGermany· 2025-06-12